Clinical Trial Update: Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the lipid-lowering effects of Alirocumab when added to ezetimibe or fenofibrate in healthy subjects; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• EZETIMIBE (EZETIMIBE)
• FENOFIBRATE (Fenofibrate)
• alirocumab (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 1 | Status: COMPLETED